nodes	percent_of_prediction	percent_of_DWPC	metapath
Plerixafor—CXCR4—Binding and entry of HIV virion—CD4—kidney cancer	0.0272	0.105	CbGpPWpGaD
Plerixafor—CXCR4—S1P3 pathway—FLT1—kidney cancer	0.0154	0.0594	CbGpPWpGaD
Plerixafor—CXCR4—renal system—kidney cancer	0.0153	0.263	CbGeAlD
Plerixafor—CXCR4—kidney—kidney cancer	0.0148	0.254	CbGeAlD
Plerixafor—CXCR4—cortex of kidney—kidney cancer	0.0144	0.247	CbGeAlD
Plerixafor—CXCR4—cardiac atrium—kidney cancer	0.0137	0.235	CbGeAlD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—PGK1—kidney cancer	0.013	0.0501	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—NDRG1—kidney cancer	0.0121	0.0466	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—CA9—kidney cancer	0.0111	0.0426	CbGpPWpGaD
Plerixafor—CXCR4—Early Phase of HIV Life Cycle—CD4—kidney cancer	0.00998	0.0384	CbGpPWpGaD
Plerixafor—CXCR4—Cardiac Progenitor Differentiation—PAX6—kidney cancer	0.00905	0.0348	CbGpPWpGaD
Plerixafor—CXCR4—HIV Life Cycle—TCEB1—kidney cancer	0.00668	0.0257	CbGpPWpGaD
Plerixafor—CXCR4—HIV Life Cycle—TCEB2—kidney cancer	0.00668	0.0257	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—SLC2A1—kidney cancer	0.00663	0.0255	CbGpPWpGaD
Plerixafor—CXCR4—Cardiac Progenitor Differentiation—IGF2—kidney cancer	0.00642	0.0247	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—PAK1—kidney cancer	0.00543	0.0209	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—ABCB1—kidney cancer	0.00524	0.0201	CbGpPWpGaD
Plerixafor—CXCR4—S1P3 pathway—VEGFA—kidney cancer	0.00491	0.0189	CbGpPWpGaD
Plerixafor—CXCR4—Cardiac Progenitor Differentiation—KDR—kidney cancer	0.00488	0.0188	CbGpPWpGaD
Plerixafor—CXCR4—S1P3 pathway—MAPK3—kidney cancer	0.00464	0.0179	CbGpPWpGaD
Plerixafor—CXCR4—HIV Infection—TCEB2—kidney cancer	0.00461	0.0177	CbGpPWpGaD
Plerixafor—CXCR4—HIV Infection—TCEB1—kidney cancer	0.00461	0.0177	CbGpPWpGaD
Plerixafor—CXCR4—Cardiac Progenitor Differentiation—KIT—kidney cancer	0.0045	0.0173	CbGpPWpGaD
Plerixafor—CXCR4—S1P3 pathway—MAPK1—kidney cancer	0.00442	0.017	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—HIF1A—kidney cancer	0.00429	0.0165	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—ANXA1—kidney cancer	0.00315	0.0121	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—OR4C13—kidney cancer	0.00307	0.0118	CbGpPWpGaD
Plerixafor—CXCR4—HIV Infection—PSMD7—kidney cancer	0.00284	0.0109	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—OR4C13—kidney cancer	0.00279	0.0107	CbGpPWpGaD
Plerixafor—CXCR4—G alpha (i) signalling events—ANXA1—kidney cancer	0.00266	0.0102	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—JUN—kidney cancer	0.00258	0.00994	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—MTOR—kidney cancer	0.00239	0.00918	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—CD4—kidney cancer	0.00238	0.00916	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—VEGFA—kidney cancer	0.00226	0.00869	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—ANXA1—kidney cancer	0.00211	0.00812	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CCBL1—kidney cancer	0.00188	0.00724	CbGpPWpGaD
Plerixafor—CXCR4—Disease—AMER1—kidney cancer	0.0017	0.00654	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—OR4C13—kidney cancer	0.00165	0.00634	CbGpPWpGaD
Plerixafor—CXCR4—HIV Life Cycle—CD4—kidney cancer	0.00162	0.00623	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—ANXA1—kidney cancer	0.00161	0.00619	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—POMC—kidney cancer	0.00154	0.00593	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—PIK3CA—kidney cancer	0.00145	0.00559	CbGpPWpGaD
Plerixafor—CXCR4—Disease—GPC3—kidney cancer	0.00143	0.00548	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—LATS1—kidney cancer	0.0014	0.00539	CbGpPWpGaD
Plerixafor—CXCR4—Disease—ST3GAL2—kidney cancer	0.00132	0.00507	CbGpPWpGaD
Plerixafor—CXCR4—G alpha (i) signalling events—POMC—kidney cancer	0.0013	0.00501	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—AKAP13—kidney cancer	0.00128	0.00491	CbGpPWpGaD
Plerixafor—Musculoskeletal discomfort—Sunitinib—kidney cancer	0.00127	0.00186	CcSEcCtD
Plerixafor—Insomnia—Sunitinib—kidney cancer	0.00126	0.00184	CcSEcCtD
Plerixafor—Nausea—Pazopanib—kidney cancer	0.00125	0.00184	CcSEcCtD
Plerixafor—Paraesthesia—Sunitinib—kidney cancer	0.00125	0.00183	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Sorafenib—kidney cancer	0.00125	0.00183	CcSEcCtD
Plerixafor—Fatigue—Sorafenib—kidney cancer	0.00125	0.00183	CcSEcCtD
Plerixafor—Dyspnoea—Sunitinib—kidney cancer	0.00124	0.00182	CcSEcCtD
Plerixafor—Pain—Sorafenib—kidney cancer	0.00124	0.00181	CcSEcCtD
Plerixafor—Constipation—Sorafenib—kidney cancer	0.00124	0.00181	CcSEcCtD
Plerixafor—CXCR4—Disease—SLC5A3—kidney cancer	0.00124	0.00475	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PGK1—kidney cancer	0.00124	0.00475	CbGpPWpGaD
Plerixafor—Malaise—Gemcitabine—kidney cancer	0.00123	0.00181	CcSEcCtD
Plerixafor—Hypersensitivity—Vinblastine—kidney cancer	0.00123	0.00181	CcSEcCtD
Plerixafor—Hypersensitivity—Everolimus—kidney cancer	0.00123	0.0018	CcSEcCtD
Plerixafor—Dyspepsia—Sunitinib—kidney cancer	0.00122	0.0018	CcSEcCtD
Plerixafor—CXCR4—Disease—LDHB—kidney cancer	0.00121	0.00466	CbGpPWpGaD
Plerixafor—CXCR4—Disease—SFRP2—kidney cancer	0.00121	0.00466	CbGpPWpGaD
Plerixafor—Gastrointestinal disorder—Sunitinib—kidney cancer	0.0012	0.00176	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Dactinomycin—kidney cancer	0.0012	0.00176	CcSEcCtD
Plerixafor—Asthenia—Vinblastine—kidney cancer	0.0012	0.00176	CcSEcCtD
Plerixafor—Fatigue—Sunitinib—kidney cancer	0.0012	0.00176	CcSEcCtD
Plerixafor—Asthenia—Everolimus—kidney cancer	0.00119	0.00175	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—AMER1—kidney cancer	0.00119	0.00458	CbGpPWpGaD
Plerixafor—Pain—Sunitinib—kidney cancer	0.00119	0.00174	CcSEcCtD
Plerixafor—Constipation—Sunitinib—kidney cancer	0.00119	0.00174	CcSEcCtD
Plerixafor—Immune system disorder—Paclitaxel—kidney cancer	0.00119	0.00174	CcSEcCtD
Plerixafor—Gastrointestinal pain—Sorafenib—kidney cancer	0.00118	0.00173	CcSEcCtD
Plerixafor—Pruritus—Everolimus—kidney cancer	0.00118	0.00173	CcSEcCtD
Plerixafor—Anaphylactic shock—Vincristine—kidney cancer	0.00118	0.00172	CcSEcCtD
Plerixafor—Arthralgia—Gemcitabine—kidney cancer	0.00116	0.00171	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—AKAP13—kidney cancer	0.00116	0.00446	CbGpPWpGaD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.00116	0.0017	CcSEcCtD
Plerixafor—Nervous system disorder—Vincristine—kidney cancer	0.00115	0.00169	CcSEcCtD
Plerixafor—Asthenia—Erlotinib—kidney cancer	0.00115	0.00169	CcSEcCtD
Plerixafor—Mental disorder—Paclitaxel—kidney cancer	0.00115	0.00169	CcSEcCtD
Plerixafor—Discomfort—Gemcitabine—kidney cancer	0.00115	0.00169	CcSEcCtD
Plerixafor—Urticaria—Sorafenib—kidney cancer	0.00115	0.00168	CcSEcCtD
Plerixafor—Erythema—Paclitaxel—kidney cancer	0.00114	0.00168	CcSEcCtD
Plerixafor—Diarrhoea—Vinblastine—kidney cancer	0.00114	0.00168	CcSEcCtD
Plerixafor—Abdominal pain—Sorafenib—kidney cancer	0.00114	0.00168	CcSEcCtD
Plerixafor—Diarrhoea—Everolimus—kidney cancer	0.00114	0.00167	CcSEcCtD
Plerixafor—Gastrointestinal pain—Sunitinib—kidney cancer	0.00114	0.00167	CcSEcCtD
Plerixafor—Hyperhidrosis—Vincristine—kidney cancer	0.00114	0.00167	CcSEcCtD
Plerixafor—Pruritus—Erlotinib—kidney cancer	0.00114	0.00167	CcSEcCtD
Plerixafor—Fatigue—Dactinomycin—kidney cancer	0.00114	0.00166	CcSEcCtD
Plerixafor—CXCR4—Disease—TCEB1—kidney cancer	0.00113	0.00435	CbGpPWpGaD
Plerixafor—CXCR4—Disease—TCEB2—kidney cancer	0.00113	0.00435	CbGpPWpGaD
Plerixafor—Flatulence—Paclitaxel—kidney cancer	0.00113	0.00165	CcSEcCtD
Plerixafor—Pain—Dactinomycin—kidney cancer	0.00113	0.00165	CcSEcCtD
Plerixafor—CXCR4—HIV Infection—CD4—kidney cancer	0.00112	0.0043	CbGpPWpGaD
Plerixafor—Anaphylactic shock—Gemcitabine—kidney cancer	0.00112	0.00164	CcSEcCtD
Plerixafor—Dizziness—Vinblastine—kidney cancer	0.00111	0.00162	CcSEcCtD
Plerixafor—Dizziness—Everolimus—kidney cancer	0.0011	0.00161	CcSEcCtD
Plerixafor—Abdominal pain—Sunitinib—kidney cancer	0.0011	0.00161	CcSEcCtD
Plerixafor—Diarrhoea—Erlotinib—kidney cancer	0.0011	0.00161	CcSEcCtD
Plerixafor—Nervous system disorder—Gemcitabine—kidney cancer	0.00109	0.0016	CcSEcCtD
Plerixafor—Feeling abnormal—Dactinomycin—kidney cancer	0.00109	0.00159	CcSEcCtD
Plerixafor—Haemoglobin—Capecitabine—kidney cancer	0.00108	0.00159	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—ITPR2—kidney cancer	0.00108	0.00417	CbGpPWpGaD
Plerixafor—Skin disorder—Gemcitabine—kidney cancer	0.00108	0.00159	CcSEcCtD
Plerixafor—Haemorrhage—Capecitabine—kidney cancer	0.00108	0.00158	CcSEcCtD
Plerixafor—Hyperhidrosis—Gemcitabine—kidney cancer	0.00108	0.00158	CcSEcCtD
Plerixafor—Gastrointestinal pain—Dactinomycin—kidney cancer	0.00108	0.00158	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Vincristine—kidney cancer	0.00107	0.00157	CcSEcCtD
Plerixafor—Hypersensitivity—Sorafenib—kidney cancer	0.00106	0.00156	CcSEcCtD
Plerixafor—Insomnia—Vincristine—kidney cancer	0.00106	0.00156	CcSEcCtD
Plerixafor—Vomiting—Vinblastine—kidney cancer	0.00106	0.00156	CcSEcCtD
Plerixafor—Dizziness—Erlotinib—kidney cancer	0.00106	0.00156	CcSEcCtD
Plerixafor—Ill-defined disorder—Paclitaxel—kidney cancer	0.00106	0.00156	CcSEcCtD
Plerixafor—Connective tissue disorder—Capecitabine—kidney cancer	0.00106	0.00155	CcSEcCtD
Plerixafor—Vomiting—Everolimus—kidney cancer	0.00106	0.00155	CcSEcCtD
Plerixafor—Paraesthesia—Vincristine—kidney cancer	0.00106	0.00155	CcSEcCtD
Plerixafor—Rash—Everolimus—kidney cancer	0.00105	0.00154	CcSEcCtD
Plerixafor—Dermatitis—Everolimus—kidney cancer	0.00105	0.00154	CcSEcCtD
Plerixafor—Headache—Vinblastine—kidney cancer	0.00105	0.00154	CcSEcCtD
Plerixafor—Headache—Everolimus—kidney cancer	0.00104	0.00153	CcSEcCtD
Plerixafor—Abdominal pain—Dactinomycin—kidney cancer	0.00104	0.00153	CcSEcCtD
Plerixafor—Asthenia—Sorafenib—kidney cancer	0.00104	0.00152	CcSEcCtD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—POMC—kidney cancer	0.00103	0.00398	CbGpPWpGaD
Plerixafor—Malaise—Paclitaxel—kidney cancer	0.00103	0.00151	CcSEcCtD
Plerixafor—Syncope—Paclitaxel—kidney cancer	0.00103	0.00151	CcSEcCtD
Plerixafor—Hypersensitivity—Sunitinib—kidney cancer	0.00102	0.0015	CcSEcCtD
Plerixafor—Pruritus—Sorafenib—kidney cancer	0.00102	0.0015	CcSEcCtD
Plerixafor—Vomiting—Erlotinib—kidney cancer	0.00102	0.0015	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.00102	0.00149	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Vincristine—kidney cancer	0.00102	0.00149	CcSEcCtD
Plerixafor—Fatigue—Vincristine—kidney cancer	0.00101	0.00149	CcSEcCtD
Plerixafor—Rash—Erlotinib—kidney cancer	0.00101	0.00149	CcSEcCtD
Plerixafor—Dermatitis—Erlotinib—kidney cancer	0.00101	0.00148	CcSEcCtD
Plerixafor—Insomnia—Gemcitabine—kidney cancer	0.00101	0.00148	CcSEcCtD
Plerixafor—Headache—Erlotinib—kidney cancer	0.00101	0.00148	CcSEcCtD
Plerixafor—Loss of consciousness—Paclitaxel—kidney cancer	0.00101	0.00148	CcSEcCtD
Plerixafor—Constipation—Vincristine—kidney cancer	0.00101	0.00147	CcSEcCtD
Plerixafor—Pain—Vincristine—kidney cancer	0.00101	0.00147	CcSEcCtD
Plerixafor—Paraesthesia—Gemcitabine—kidney cancer	0.001	0.00147	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—GPC3—kidney cancer	0.000998	0.00384	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CER1—kidney cancer	0.000998	0.00384	CbGpPWpGaD
Plerixafor—Asthenia—Sunitinib—kidney cancer	0.000998	0.00146	CcSEcCtD
Plerixafor—Dyspnoea—Gemcitabine—kidney cancer	0.000995	0.00146	CcSEcCtD
Plerixafor—Nausea—Vinblastine—kidney cancer	0.000993	0.00146	CcSEcCtD
Plerixafor—Nausea—Everolimus—kidney cancer	0.000989	0.00145	CcSEcCtD
Plerixafor—Diarrhoea—Sorafenib—kidney cancer	0.000989	0.00145	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—ITPR2—kidney cancer	0.000985	0.00379	CbGpPWpGaD
Plerixafor—Pruritus—Sunitinib—kidney cancer	0.000984	0.00144	CcSEcCtD
Plerixafor—Immune system disorder—Capecitabine—kidney cancer	0.000975	0.00143	CcSEcCtD
Plerixafor—Arthralgia—Paclitaxel—kidney cancer	0.000975	0.00143	CcSEcCtD
Plerixafor—Hypersensitivity—Dactinomycin—kidney cancer	0.00097	0.00142	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000968	0.00142	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000963	0.00141	CcSEcCtD
Plerixafor—Discomfort—Paclitaxel—kidney cancer	0.000963	0.00141	CcSEcCtD
Plerixafor—Fatigue—Gemcitabine—kidney cancer	0.000962	0.00141	CcSEcCtD
Plerixafor—Gastrointestinal pain—Vincristine—kidney cancer	0.000962	0.00141	CcSEcCtD
Plerixafor—Dizziness—Sorafenib—kidney cancer	0.000956	0.0014	CcSEcCtD
Plerixafor—Pain—Gemcitabine—kidney cancer	0.000954	0.0014	CcSEcCtD
Plerixafor—Constipation—Gemcitabine—kidney cancer	0.000954	0.0014	CcSEcCtD
Plerixafor—Nausea—Erlotinib—kidney cancer	0.000954	0.0014	CcSEcCtD
Plerixafor—Dry mouth—Paclitaxel—kidney cancer	0.000953	0.0014	CcSEcCtD
Plerixafor—Diarrhoea—Sunitinib—kidney cancer	0.000952	0.0014	CcSEcCtD
Plerixafor—Mental disorder—Capecitabine—kidney cancer	0.000946	0.00139	CcSEcCtD
Plerixafor—Asthenia—Dactinomycin—kidney cancer	0.000945	0.00139	CcSEcCtD
Plerixafor—Erythema—Capecitabine—kidney cancer	0.00094	0.00138	CcSEcCtD
Plerixafor—Anaphylactic shock—Paclitaxel—kidney cancer	0.000934	0.00137	CcSEcCtD
Plerixafor—Abdominal pain—Vincristine—kidney cancer	0.00093	0.00136	CcSEcCtD
Plerixafor—Flatulence—Capecitabine—kidney cancer	0.000926	0.00136	CcSEcCtD
Plerixafor—Dizziness—Sunitinib—kidney cancer	0.00092	0.00135	CcSEcCtD
Plerixafor—Feeling abnormal—Gemcitabine—kidney cancer	0.00092	0.00135	CcSEcCtD
Plerixafor—Shock—Paclitaxel—kidney cancer	0.000919	0.00135	CcSEcCtD
Plerixafor—Vomiting—Sorafenib—kidney cancer	0.000919	0.00135	CcSEcCtD
Plerixafor—CXCR4—Disease—RPL14—kidney cancer	0.000918	0.00353	CbGpPWpGaD
Plerixafor—Orthostatic hypotension—Doxorubicin—kidney cancer	0.000918	0.00135	CcSEcCtD
Plerixafor—Nervous system disorder—Paclitaxel—kidney cancer	0.000916	0.00134	CcSEcCtD
Plerixafor—Rash—Sorafenib—kidney cancer	0.000911	0.00134	CcSEcCtD
Plerixafor—Dermatitis—Sorafenib—kidney cancer	0.000911	0.00133	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—ANXA1—kidney cancer	0.000909	0.0035	CbGpPWpGaD
Plerixafor—Skin disorder—Paclitaxel—kidney cancer	0.000908	0.00133	CcSEcCtD
Plerixafor—Headache—Sorafenib—kidney cancer	0.000905	0.00133	CcSEcCtD
Plerixafor—Hyperhidrosis—Paclitaxel—kidney cancer	0.000903	0.00132	CcSEcCtD
Plerixafor—Diarrhoea—Dactinomycin—kidney cancer	0.000901	0.00132	CcSEcCtD
Plerixafor—Vomiting—Sunitinib—kidney cancer	0.000884	0.0013	CcSEcCtD
Plerixafor—Rash—Sunitinib—kidney cancer	0.000877	0.00129	CcSEcCtD
Plerixafor—Dermatitis—Sunitinib—kidney cancer	0.000876	0.00128	CcSEcCtD
Plerixafor—Abdominal distension—Doxorubicin—kidney cancer	0.000875	0.00128	CcSEcCtD
Plerixafor—Ill-defined disorder—Capecitabine—kidney cancer	0.000872	0.00128	CcSEcCtD
Plerixafor—Headache—Sunitinib—kidney cancer	0.000871	0.00128	CcSEcCtD
Plerixafor—Hypersensitivity—Vincristine—kidney cancer	0.000867	0.00127	CcSEcCtD
Plerixafor—Nausea—Sorafenib—kidney cancer	0.000859	0.00126	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000851	0.00125	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—SFRP2—kidney cancer	0.000849	0.00327	CbGpPWpGaD
Plerixafor—Malaise—Capecitabine—kidney cancer	0.000847	0.00124	CcSEcCtD
Plerixafor—Insomnia—Paclitaxel—kidney cancer	0.000845	0.00124	CcSEcCtD
Plerixafor—Asthenia—Vincristine—kidney cancer	0.000844	0.00124	CcSEcCtD
Plerixafor—Syncope—Capecitabine—kidney cancer	0.000843	0.00124	CcSEcCtD
Plerixafor—Paraesthesia—Paclitaxel—kidney cancer	0.000839	0.00123	CcSEcCtD
Plerixafor—Vomiting—Dactinomycin—kidney cancer	0.000837	0.00123	CcSEcCtD
Plerixafor—Dyspnoea—Paclitaxel—kidney cancer	0.000833	0.00122	CcSEcCtD
Plerixafor—CXCR4—Disease—ITPR2—kidney cancer	0.000831	0.0032	CbGpPWpGaD
Plerixafor—Rash—Dactinomycin—kidney cancer	0.00083	0.00122	CcSEcCtD
Plerixafor—Nausea—Sunitinib—kidney cancer	0.000826	0.00121	CcSEcCtD
Plerixafor—Loss of consciousness—Capecitabine—kidney cancer	0.000826	0.00121	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—ANXA1—kidney cancer	0.000825	0.00317	CbGpPWpGaD
Plerixafor—Dyspepsia—Paclitaxel—kidney cancer	0.000822	0.00121	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000807	0.00118	CcSEcCtD
Plerixafor—Fatigue—Paclitaxel—kidney cancer	0.000806	0.00118	CcSEcCtD
Plerixafor—Diarrhoea—Vincristine—kidney cancer	0.000805	0.00118	CcSEcCtD
Plerixafor—Asthenia—Gemcitabine—kidney cancer	0.000801	0.00117	CcSEcCtD
Plerixafor—Arthralgia—Capecitabine—kidney cancer	0.0008	0.00117	CcSEcCtD
Plerixafor—Pain—Paclitaxel—kidney cancer	0.000799	0.00117	CcSEcCtD
Plerixafor—Constipation—Paclitaxel—kidney cancer	0.000799	0.00117	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000794	0.00116	CcSEcCtD
Plerixafor—Discomfort—Capecitabine—kidney cancer	0.00079	0.00116	CcSEcCtD
Plerixafor—Pruritus—Gemcitabine—kidney cancer	0.00079	0.00116	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—POMC—kidney cancer	0.000788	0.00303	CbGpPWpGaD
Plerixafor—Dry mouth—Capecitabine—kidney cancer	0.000782	0.00115	CcSEcCtD
Plerixafor—Nausea—Dactinomycin—kidney cancer	0.000782	0.00115	CcSEcCtD
Plerixafor—Dizziness—Vincristine—kidney cancer	0.000778	0.00114	CcSEcCtD
Plerixafor—Feeling abnormal—Paclitaxel—kidney cancer	0.00077	0.00113	CcSEcCtD
Plerixafor—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000764	0.00112	CcSEcCtD
Plerixafor—Diarrhoea—Gemcitabine—kidney cancer	0.000764	0.00112	CcSEcCtD
Plerixafor—Shock—Capecitabine—kidney cancer	0.000754	0.00111	CcSEcCtD
Plerixafor—Nervous system disorder—Capecitabine—kidney cancer	0.000752	0.0011	CcSEcCtD
Plerixafor—Vomiting—Vincristine—kidney cancer	0.000748	0.0011	CcSEcCtD
Plerixafor—Skin disorder—Capecitabine—kidney cancer	0.000745	0.00109	CcSEcCtD
Plerixafor—Urticaria—Paclitaxel—kidney cancer	0.000742	0.00109	CcSEcCtD
Plerixafor—Rash—Vincristine—kidney cancer	0.000742	0.00109	CcSEcCtD
Plerixafor—Hyperhidrosis—Capecitabine—kidney cancer	0.000741	0.00109	CcSEcCtD
Plerixafor—Dermatitis—Vincristine—kidney cancer	0.000741	0.00109	CcSEcCtD
Plerixafor—Abdominal pain—Paclitaxel—kidney cancer	0.000739	0.00108	CcSEcCtD
Plerixafor—Headache—Vincristine—kidney cancer	0.000737	0.00108	CcSEcCtD
Plerixafor—Vomiting—Gemcitabine—kidney cancer	0.00071	0.00104	CcSEcCtD
Plerixafor—Rash—Gemcitabine—kidney cancer	0.000704	0.00103	CcSEcCtD
Plerixafor—Dermatitis—Gemcitabine—kidney cancer	0.000703	0.00103	CcSEcCtD
Plerixafor—Haemoglobin—Doxorubicin—kidney cancer	0.000699	0.00103	CcSEcCtD
Plerixafor—Headache—Gemcitabine—kidney cancer	0.000699	0.00103	CcSEcCtD
Plerixafor—Nausea—Vincristine—kidney cancer	0.000699	0.00102	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000699	0.00102	CcSEcCtD
Plerixafor—CXCR4—Disease—PSMD7—kidney cancer	0.000696	0.00268	CbGpPWpGaD
Plerixafor—Haemorrhage—Doxorubicin—kidney cancer	0.000696	0.00102	CcSEcCtD
Plerixafor—Insomnia—Capecitabine—kidney cancer	0.000694	0.00102	CcSEcCtD
Plerixafor—Paraesthesia—Capecitabine—kidney cancer	0.000689	0.00101	CcSEcCtD
Plerixafor—Hypersensitivity—Paclitaxel—kidney cancer	0.000688	0.00101	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—AKAP13—kidney cancer	0.000684	0.00263	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CASP2—kidney cancer	0.000684	0.00263	CbGpPWpGaD
Plerixafor—Connective tissue disorder—Doxorubicin—kidney cancer	0.000684	0.001	CcSEcCtD
Plerixafor—Dyspnoea—Capecitabine—kidney cancer	0.000684	0.001	CcSEcCtD
Plerixafor—Dyspepsia—Capecitabine—kidney cancer	0.000675	0.00099	CcSEcCtD
Plerixafor—Asthenia—Paclitaxel—kidney cancer	0.00067	0.000983	CcSEcCtD
Plerixafor—Nausea—Gemcitabine—kidney cancer	0.000663	0.000972	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000662	0.000971	CcSEcCtD
Plerixafor—Fatigue—Capecitabine—kidney cancer	0.000661	0.000969	CcSEcCtD
Plerixafor—Pruritus—Paclitaxel—kidney cancer	0.000661	0.000969	CcSEcCtD
Plerixafor—Pain—Capecitabine—kidney cancer	0.000656	0.000961	CcSEcCtD
Plerixafor—Constipation—Capecitabine—kidney cancer	0.000656	0.000961	CcSEcCtD
Plerixafor—Diarrhoea—Paclitaxel—kidney cancer	0.000639	0.000937	CcSEcCtD
Plerixafor—Feeling abnormal—Capecitabine—kidney cancer	0.000632	0.000926	CcSEcCtD
Plerixafor—CXCR4—Disease—SLC2A1—kidney cancer	0.00063	0.00242	CbGpPWpGaD
Plerixafor—Immune system disorder—Doxorubicin—kidney cancer	0.000628	0.000921	CcSEcCtD
Plerixafor—Gastrointestinal pain—Capecitabine—kidney cancer	0.000627	0.000919	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—GRB7—kidney cancer	0.000626	0.00241	CbGpPWpGaD
Plerixafor—CXCR4—Disease—JUNB—kidney cancer	0.000625	0.0024	CbGpPWpGaD
Plerixafor—Dizziness—Paclitaxel—kidney cancer	0.000618	0.000906	CcSEcCtD
Plerixafor—Mental disorder—Doxorubicin—kidney cancer	0.000609	0.000894	CcSEcCtD
Plerixafor—Urticaria—Capecitabine—kidney cancer	0.000609	0.000893	CcSEcCtD
Plerixafor—Abdominal pain—Capecitabine—kidney cancer	0.000606	0.000889	CcSEcCtD
Plerixafor—Erythema—Doxorubicin—kidney cancer	0.000606	0.000888	CcSEcCtD
Plerixafor—Flatulence—Doxorubicin—kidney cancer	0.000597	0.000875	CcSEcCtD
Plerixafor—Vomiting—Paclitaxel—kidney cancer	0.000594	0.000871	CcSEcCtD
Plerixafor—Rash—Paclitaxel—kidney cancer	0.000589	0.000864	CcSEcCtD
Plerixafor—Dermatitis—Paclitaxel—kidney cancer	0.000589	0.000863	CcSEcCtD
Plerixafor—Headache—Paclitaxel—kidney cancer	0.000585	0.000858	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—ITPR2—kidney cancer	0.000582	0.00224	CbGpPWpGaD
Plerixafor—Hypersensitivity—Capecitabine—kidney cancer	0.000565	0.000828	CcSEcCtD
Plerixafor—Ill-defined disorder—Doxorubicin—kidney cancer	0.000562	0.000824	CcSEcCtD
Plerixafor—Nausea—Paclitaxel—kidney cancer	0.000555	0.000814	CcSEcCtD
Plerixafor—Asthenia—Capecitabine—kidney cancer	0.00055	0.000807	CcSEcCtD
Plerixafor—Malaise—Doxorubicin—kidney cancer	0.000546	0.000801	CcSEcCtD
Plerixafor—Syncope—Doxorubicin—kidney cancer	0.000543	0.000796	CcSEcCtD
Plerixafor—Pruritus—Capecitabine—kidney cancer	0.000542	0.000795	CcSEcCtD
Plerixafor—Loss of consciousness—Doxorubicin—kidney cancer	0.000532	0.00078	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—CTNNA1—kidney cancer	0.000527	0.00203	CbGpPWpGaD
Plerixafor—Diarrhoea—Capecitabine—kidney cancer	0.000525	0.000769	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—HSPB1—kidney cancer	0.000524	0.00202	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—EIF4EBP1—kidney cancer	0.000524	0.00202	CbGpPWpGaD
Plerixafor—Arthralgia—Doxorubicin—kidney cancer	0.000516	0.000756	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000512	0.000751	CcSEcCtD
Plerixafor—Discomfort—Doxorubicin—kidney cancer	0.000509	0.000747	CcSEcCtD
Plerixafor—CXCR4—Disease—CDKN2B—kidney cancer	0.000509	0.00196	CbGpPWpGaD
Plerixafor—Dizziness—Capecitabine—kidney cancer	0.000507	0.000743	CcSEcCtD
Plerixafor—Dry mouth—Doxorubicin—kidney cancer	0.000504	0.000739	CcSEcCtD
Plerixafor—Anaphylactic shock—Doxorubicin—kidney cancer	0.000494	0.000725	CcSEcCtD
Plerixafor—Vomiting—Capecitabine—kidney cancer	0.000488	0.000715	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PSMD7—kidney cancer	0.000487	0.00188	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TSC1—kidney cancer	0.000487	0.00188	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—ANXA1—kidney cancer	0.000487	0.00188	CbGpPWpGaD
Plerixafor—Shock—Doxorubicin—kidney cancer	0.000486	0.000713	CcSEcCtD
Plerixafor—Nervous system disorder—Doxorubicin—kidney cancer	0.000485	0.000711	CcSEcCtD
Plerixafor—Rash—Capecitabine—kidney cancer	0.000483	0.000709	CcSEcCtD
Plerixafor—Dermatitis—Capecitabine—kidney cancer	0.000483	0.000708	CcSEcCtD
Plerixafor—Headache—Capecitabine—kidney cancer	0.00048	0.000704	CcSEcCtD
Plerixafor—Skin disorder—Doxorubicin—kidney cancer	0.00048	0.000704	CcSEcCtD
Plerixafor—Hyperhidrosis—Doxorubicin—kidney cancer	0.000478	0.000701	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—FLT1—kidney cancer	0.000472	0.00182	CbGpPWpGaD
Plerixafor—Nausea—Capecitabine—kidney cancer	0.000455	0.000668	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.00045	0.00066	CcSEcCtD
Plerixafor—Insomnia—Doxorubicin—kidney cancer	0.000447	0.000655	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—POMC—kidney cancer	0.000445	0.00171	CbGpPWpGaD
Plerixafor—Paraesthesia—Doxorubicin—kidney cancer	0.000444	0.000651	CcSEcCtD
Plerixafor—Dyspnoea—Doxorubicin—kidney cancer	0.000441	0.000646	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—JUNB—kidney cancer	0.000438	0.00168	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PAK1—kidney cancer	0.000438	0.00168	CbGpPWpGaD
Plerixafor—Dyspepsia—Doxorubicin—kidney cancer	0.000435	0.000638	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000427	0.000626	CcSEcCtD
Plerixafor—Fatigue—Doxorubicin—kidney cancer	0.000426	0.000625	CcSEcCtD
Plerixafor—Pain—Doxorubicin—kidney cancer	0.000423	0.00062	CcSEcCtD
Plerixafor—Constipation—Doxorubicin—kidney cancer	0.000423	0.00062	CcSEcCtD
Plerixafor—Feeling abnormal—Doxorubicin—kidney cancer	0.000407	0.000597	CcSEcCtD
Plerixafor—CXCR4—Disease—HIF1A—kidney cancer	0.000407	0.00156	CbGpPWpGaD
Plerixafor—CXCR4—Disease—TSC2—kidney cancer	0.000406	0.00156	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—POMC—kidney cancer	0.000404	0.00156	CbGpPWpGaD
Plerixafor—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000404	0.000593	CcSEcCtD
Plerixafor—Urticaria—Doxorubicin—kidney cancer	0.000393	0.000576	CcSEcCtD
Plerixafor—Abdominal pain—Doxorubicin—kidney cancer	0.000391	0.000573	CcSEcCtD
Plerixafor—Hypersensitivity—Doxorubicin—kidney cancer	0.000364	0.000534	CcSEcCtD
Plerixafor—CXCR4—Disease—KIT—kidney cancer	0.000358	0.00138	CbGpPWpGaD
Plerixafor—CXCR4—Disease—APC—kidney cancer	0.000358	0.00138	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IGF2—kidney cancer	0.000358	0.00138	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CDKN2B—kidney cancer	0.000356	0.00137	CbGpPWpGaD
Plerixafor—Asthenia—Doxorubicin—kidney cancer	0.000355	0.00052	CcSEcCtD
Plerixafor—Pruritus—Doxorubicin—kidney cancer	0.00035	0.000513	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—IGF1R—kidney cancer	0.000346	0.00133	CbGpPWpGaD
Plerixafor—Diarrhoea—Doxorubicin—kidney cancer	0.000338	0.000496	CcSEcCtD
Plerixafor—CXCR4—Disease—BRAF—kidney cancer	0.000337	0.0013	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—RAF1—kidney cancer	0.000333	0.00128	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—IL2—kidney cancer	0.000329	0.00127	CbGpPWpGaD
Plerixafor—Dizziness—Doxorubicin—kidney cancer	0.000327	0.000479	CcSEcCtD
Plerixafor—Vomiting—Doxorubicin—kidney cancer	0.000314	0.000461	CcSEcCtD
Plerixafor—Rash—Doxorubicin—kidney cancer	0.000312	0.000457	CcSEcCtD
Plerixafor—Dermatitis—Doxorubicin—kidney cancer	0.000311	0.000457	CcSEcCtD
Plerixafor—Headache—Doxorubicin—kidney cancer	0.00031	0.000454	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—IL2—kidney cancer	0.000299	0.00115	CbGpPWpGaD
Plerixafor—Nausea—Doxorubicin—kidney cancer	0.000294	0.00043	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—HIF1A—kidney cancer	0.000285	0.0011	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TSC2—kidney cancer	0.000284	0.00109	CbGpPWpGaD
Plerixafor—CXCR4—Disease—RAF1—kidney cancer	0.000281	0.00108	CbGpPWpGaD
Plerixafor—CXCR4—Disease—ERBB2—kidney cancer	0.000278	0.00107	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MTOR—kidney cancer	0.000275	0.00106	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CD4—kidney cancer	0.000274	0.00105	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—KDR—kidney cancer	0.000272	0.00105	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PTGS2—kidney cancer	0.000272	0.00105	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CDKN1B—kidney cancer	0.000258	0.000991	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—APC—kidney cancer	0.000251	0.000965	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—KIT—kidney cancer	0.000251	0.000965	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CTNNB1—kidney cancer	0.000243	0.000936	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—MAPK3—kidney cancer	0.00024	0.000924	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—POMC—kidney cancer	0.000239	0.000919	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PTEN—kidney cancer	0.000237	0.000913	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—BRAF—kidney cancer	0.000236	0.000907	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—MAPK1—kidney cancer	0.000229	0.00088	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CA—kidney cancer	0.000218	0.000841	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—KRAS—kidney cancer	0.000216	0.000831	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MAPK3—kidney cancer	0.000203	0.00078	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CA—kidney cancer	0.000198	0.000763	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MYC—kidney cancer	0.000197	0.000758	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—RAF1—kidney cancer	0.000197	0.000758	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—RELA—kidney cancer	0.000196	0.000754	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—ERBB2—kidney cancer	0.000195	0.00075	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MAPK1—kidney cancer	0.000193	0.000742	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MTOR—kidney cancer	0.000192	0.00074	CbGpPWpGaD
Plerixafor—CXCR4—Disease—KRAS—kidney cancer	0.000182	0.000701	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CDKN1B—kidney cancer	0.00018	0.000694	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IL2—kidney cancer	0.000177	0.000679	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CCND1—kidney cancer	0.000172	0.000662	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—JUN—kidney cancer	0.000172	0.000661	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CTNNB1—kidney cancer	0.00017	0.000656	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PIK3CA—kidney cancer	0.000167	0.000644	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PTEN—kidney cancer	0.000166	0.000639	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—VEGFA—kidney cancer	0.00015	0.000577	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MAPK3—kidney cancer	0.000142	0.000546	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MYC—kidney cancer	0.000138	0.000531	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MAPK1—kidney cancer	0.000135	0.00052	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—KRAS—kidney cancer	0.000128	0.000491	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CA—kidney cancer	0.000117	0.000451	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TP53—kidney cancer	0.000113	0.000436	CbGpPWpGaD
